Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

• Published in: Blood Vol. 97; no. 12; pp. 3746 - 3754
• Main Authors: Grote, Deanna, Russell, Stephen J., Cornu, Tatjana I., Cattaneo, Roberto, Vile, Richard, Poland, Gregory A., Fielding, Adele K.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15.06.2001; The Americain Society of Hematology
• Subjects: Animals; Antibodies, Viral - pharmacology; beta-Galactosidase - genetics; Biological and medical sciences; Cytopathogenic Effect, Viral - physiology; Genes, Reporter; Humans; Immunohistochemistry; Lymphoma - pathology; Lymphoma - therapy; Measles virus - growth & development; Medical sciences; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Other treatments; Time Factors; Transplantation, Heterologous; Treatment. General aspects; Tumor Cells, Cultured; Tumors; Vaccines, Attenuated - standards; Vaccines, Attenuated - therapeutic use; Antineoplastic agent; Animal model; Transplantation; Heterotransplantation; Paramyxoviridae; Surgery; Lymphoproliferative syndrome; Morbillivirus; Oncolysis; Tumor cell; β-Galactosidase; Measles virus; Human; Enzyme; Vaccine strain; Rodentia; Malignant hemopathy; B-Lymphocyte; Lymphoma; Virus; Paramyxovirinae; Mononegavirales; Vertebrata; Mammalia; Treatment; Mouse; Glycosidases; Hydrolases; Attenuated strain; O-Glycosidases
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V97.12.3746

Derivatives of the Edmonston-B strain of measles virus (MV-Ed) are safe, live attenuated measles virus (MV) vaccines that have been used worldwide for more than 30 years. The cytoreductive potential of MV-Ed has been investigated in murine models of both aggressive and indolent B-cell lymphoma in severe combined immunodeficient (SCID) mice. The rationale for these studies was generated by experience with viral fusogenic membrane glycoproteins as cytotoxic genes and the recognition of the potential of replicating viruses in the treatment of human malignancy. Intratumoral injection of both unmodified MV-Ed and a strain of MV-Ed genetically modified by the addition of a β-galactosidase reporter gene (MVlacZ) induced regression of large established human lymphoma xenografts, in contrast to control therapy with UV-inactivated virus, in which all tumors progressed. The antitumor effect still occurred in the presence of passively transferred anti-MV antibody. Intravenous administration of MV also resulted in considerable slowing of tumor progression. Analysis of sections of residual tumor confirmed replication of MV within the tumors. Thus, the vaccine strain of MV mediates regression of large, established human B-cell lymphoma xenografts in SCID mice, and proof of principle is established that MV is oncolytic for lymphomas in vivo. Attenuated MVs may have value as a novel replicating-virus therapy for this group of disorders.